BioMarin CEO granted options and RSUs

BioMarin Pharmaceutical CEO Alexander Hardy reported new equity awards and a routine tax withholding.

Rhea-AI Filing Summary

BioMarin Pharmaceutical CEO Alexander Hardy reported new equity awards and a routine tax withholding. On March 16, 2026, he received a grant of 89,200 stock options to buy common stock at an exercise price of $57.43 per share, expiring on March 15, 2036. The option grant vests 12/48 on March 16, 2027 and 1/48 on the 16th day of each month thereafter. He was also granted 62,440 restricted stock units on the same date, with price not applicable. On March 13, 2026, 2,941 shares of common stock were withheld at $58.51 per share to cover tax obligations. Following these transactions, Hardy directly owned 218,887 shares of BioMarin common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Hardy Alexander

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy Common Stock)	89,200	$0.00	$0.00
Grant/Award	Common Stock	62,440	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	2,941	$58.51	$172K

Holdings After Transaction: Stock Option (Right to Buy Common Stock) — 89,200 contracts (Direct); Common Stock — 218,887 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units granted March 16, 2026. Price not applicable.
2. F2. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

FAQ

What equity awards did BioMarin (BMRN) CEO Alexander Hardy receive?

Alexander Hardy received 89,200 stock options and 62,440 restricted stock units as compensation awards. The options allow him to buy BioMarin common stock at an exercise price of $57.43 per share and expire on March 15, 2036.

How do Alexander Hardy’s new BioMarin stock options vest?

The 89,200 stock options vest 12/48 on March 16, 2027, then 1/48 on the 16th day of each following month. This creates a multi-year vesting schedule, aligning Hardy’s compensation with longer-term BioMarin performance and retention.

What was the tax withholding transaction disclosed for BioMarin CEO Hardy?

On March 13, 2026, 2,941 shares of BioMarin common stock were withheld at $58.51 per share for tax obligations. This Form 4 code F transaction reflects payment of tax liability in shares, not an open-market sale by Hardy.

How many BioMarin (BMRN) shares does CEO Alexander Hardy hold after these transactions?

After the reported grant and tax-withholding transactions, Alexander Hardy directly owned 218,887 shares of BioMarin common stock. This total reflects his updated direct equity position as reported in the Form 4 filing on the SEC’s system.

Are Alexander Hardy’s new BioMarin equity awards open-market purchases?

No, the awards are not open-market purchases. The Form 4 shows code A grants: 89,200 stock options and 62,440 restricted stock units, both issued as compensation. These are company-granted awards rather than shares bought on an exchange.

What is the exercise price and expiration date of Hardy’s BioMarin stock options?

The 89,200 stock options granted to Alexander Hardy have an exercise price of $57.43 per share and expire on March 15, 2036. He can acquire BioMarin common stock at that price once the options vest over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 08:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hardy Alexander

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC

770 LINDARO STREET

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		F		2,941	D	$58.51	156,447	D
Common Stock	03/16/2026		A		62,440	A	$0(1)	218,887	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$57.43	03/16/2026		A		89,200		03/16/2027(2)	03/15/2036	Common Stock	89,200	$0	89,200	D

Explanation of Responses:

1. Restricted stock units granted March 16, 2026. Price not applicable.

2. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.